Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29713462 | 1.00 | KDM4E (0.40) | KDM4EALDH1A1HPGDHSD17B10CYP11B1 | |
| SCHEMBL23106711 | 0.83 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10CYP11B1 | |
| SCHEMBL14719869 | 0.81 | KDM4E (0.37) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15878725 | 0.77 | HTR2C (0.37) | — | |
| SCHEMBL30515523 | 0.72 | HTR2C (0.51) | — | |
| SCHEMBL5094518 | 0.72 | HTR2C (0.51) | — | |
| SCHEMBL14896356 | 0.71 | CYP11B1 (0.40) | KDM4EALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL21873149 | 0.70 | CYP11B1 (0.30) | CYP11B1CYP11B2 | |
| SCHEMBL29713454 | 0.70 | CYP11B1 (0.30) | CYP11B1CYP11B2 | |
| SCHEMBL4022294 | 0.70 | CYP11B1 (0.35) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180509-B2 | Thiazolidone spiro pyrimidine trione compound, preparation method therefor and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-11-23 | — | — | US | disclosed |
| US-11180509-B2 | Thiazolidone spiro pyrimidine trione compound, preparation method therefor and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20210079019-A1 | THIAZOLIDONE SPIRO PYRIMIDINE TRIONE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-03-18 | — | — | US | disclosed |
| US-20210079019-A1 | THIAZOLIDONE SPIRO PYRIMIDINE TRIONE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-03-18 | — | — | US | disclosed |
| EP-3643719-A1 | THIAZOLIDONE SPIRO PYRIMIDINE TRIONE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643719-A1 | THIAZOLIDONE SPIRO PYRIMIDINE TRIONE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079019-A1 | THIAZOLIDONE SPIRO PYRIMIDINE TRIONE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF | DHPS, WEE1, TYMS | KDM4E 4414/4885ALDH1A1 250/4885HPGD 558/4885 |
| US-11180509-B2 | Thiazolidone spiro pyrimidine trione compound, preparation method therefor and uses thereof | DHPS, WEE1, TYMS | KDM4E 4414/4885ALDH1A1 250/4885HPGD 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.